Search clinical trials for: CHF 5074

Total 2608 results

CERESPIR

Completed

Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects (CT03)

Alzheimer's Disease

United States
CERESPIR

Completed

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 (CT04)

Alzheimer's Disease

United States, Italy
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (CT04 POLEP)

Alzheimer's Disease

United States, Italy
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)

Alzheimer's Disease

United States, Italy
CERESPIR

Withdrawn

Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment (CT05)

Alzheimer's Disease
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
KBP Biosciences
Covance

Completed

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Healthy

United States
KBP Biosciences

Completed

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

Healthy
KBP Biosciences

Active, not recruiting

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe CKD (Clarion-CKD)

Chronic Kidney Diseases

China, Spain, Australia, Hungary, Malaysia, United States, Germany, Bulgaria, Serbia, Hong Kong, Georgia, Bosnia and Herzegovina, Croatia, Czechia, South Africa, Canada, Israel, Korea, Republic of, Latvia, Lithuania, Poland, Taiwan
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5024 Safety and PK in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Charite University, Berlin, Germany

Terminated

Action of Caffeinated and Decaffeinated Espresso on Autonomic Function

Influence of Espresso on Heart Rate Variability

Germany
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
Synvista Therapeutics, Inc

Completed

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Coronary Artery Disease | Diabetes

United States
Gazi University

Completed

Gingival Recession Treatment With Concentrated Growth Factor(CGF)

Gingival Recession
KBP Biosciences
Medpace, Inc.

Completed

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

Bioequivalence

United States
PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
Chiesi Farmaceutici S.p.A.
SGS S.A.

Completed

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

COPD

United Kingdom
Bulent Ecevit University

Completed

Growth Factors in the Treatment of the Multiple Gingival Recessions

Gingival Recession | Growth Factors, Combined Defect of

Turkey
KBP Biosciences

Completed

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

Chronic Kidney Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United States, Canada
MedImmune LLC

Completed

Study of MEDI 507 in the Treatment of Pediatric Patients (Pediatric GvHD)

Graft Versus Host Disease

United States
CERESPIR

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects (CT01)

Alzheimer's Disease

United States
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
MedImmune LLC

Completed

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Kidney Diseases

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
MedImmune LLC

Terminated

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Lymphoproliferative Disorders

United States
Samsung Electronics
Nexus DX

Terminated

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

Congestive Heart Failure

United States
International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
MedImmune LLC

Completed

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Cancer | Graft-Versus-Host Disease

United States
MedImmune LLC

Terminated

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma | Leukemia | Cancer

United States
Bayer

Completed

Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain

Endometriosis

Spain, Sweden, France, Finland, Denmark, Netherlands, Czech Republic
OPKO Health, Inc.

Completed

A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

Hemophilia A or B With Inhibitors

Israel
Monell Chemical Senses Center
Children's Hospital of Philadelphia; University of Wisconsin, Madison; University...

Completed

Effect of Infant Formula on Energy Balance (GRO)

Development

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
OPKO Health, Inc.

Completed

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Hemophilia A | Hemophilia B

United States
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited
Monash University; Sir Charles Gairdner Hospital; Austin Hospital, Melbourne...

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumor

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Dual bNAb Treatment in Children

HIV Infection

Botswana
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China
Hutchison Medipharma Limited

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumors

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Volitinib in Healthy Subjects (HMPL-504)

Food Effect | Health Subjects

China
Ferndale Laboratories, Inc.

Completed

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa (ACACIA)

HIV-1-infection
NuMe Health
Pennington Biomedical Research Center

Completed

Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin

Type 2 Diabetes

United States

3

Subscribe